121 results on '"Martinelli, Giovanni"'
Search Results
2. The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study
3. Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
4. Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment
5. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
6. Geofluids Hosted in the Deep Crust: From Systematics to Parametrization of their Significance
7. Lineage‐specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture
8. Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series
9. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
10. Next‐generation sequencing improves BCR‐ABL1 mutation detection in Philadelphia chromosome‐positive acute lymphoblastic leukaemia
11. Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia
12. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
13. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma
14. Clinical and biological data on the use of hydroxychloroquine against SARS‐CoV‐2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease
15. ABVD vs BEACOPP escalated in advanced‐stage Hodgkin’s lymphoma: Results from a multicenter European study
16. Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia
17. MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia
18. Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis
19. Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia
20. Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?
21. Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors
22. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia
23. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin
24. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery
25. Aneuploidy: Cancer strength or vulnerability?
26. Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
27. Flai (fludarabine, cytarabine, idarubicin) plus low‐dose Gemtuzumab Ozogamicin as induction therapy in CD33‐positive AML: Final results and long term outcome of a phase II multicenter clinical trial
28. FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage
29. Comparison ofJAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology
30. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation
31. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line
32. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
33. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients
34. Present and future of molecular monitoring in chronic myeloid leukaemia
35. FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features
36. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities
37. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)
38. Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐up
39. DNA Methyltransferase 1 Drives Transcriptional Down-Modulation of β Catenin Antagonist Chibby1 Associated With theBCR-ABL1Gene of Chronic Myeloid Leukemia
40. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi
41. Germline polymorphisms and survival of lung adenocarcinoma patients: A genome‐wide study in two European patient series
42. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study
43. Core needle biopsy as a front line diagnostic approach for lymphoma patients
44. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
45. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era
46. Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement
47. Prevalence of Achromobacter xylosoxidans in pulmonary mucosa‐associated lymphoid tissue lymphoma in different regions of Europe
48. Long-term molecular remission with persistence ofBCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL
49. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma
50. Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.